Intrauterine insemination with donor sperm (IUI-D) is an assisted reproductive technology (ART) offered to couples with definitive male infertility or risk of genetic disease transmission. Here, we sought to evaluate our practice in IUI-D and identify factors that influenced the success rate. We performed a retrospective, single-center study of all IUI-D procedures performed at Lille University Medical Center (Lille, France) between January 1, 2007, and December 31, 2017. Single and multivariate analyses with a mixed logistic model were used to identify factors associated with clinical pregnancies and live births. We included 322 couples and 1179 IUI-D procedures. The clinical pregnancy rate was 23.5%, and the live birth rate was 18.9% per IUI-D. In a multivariate analysis, the women’s age was negatively associated with the live birth rate. The number of motile spermatozoa inseminated was the only factor associated with both pregnancies and live births, with a chosen threshold of 0.75 million. The clinical pregnancy and live birth rates were, respectively, 17.3% and 13.0% below the number of motile spermatozoa inseminated threshold and 25.9% and 21.0% at or above the threshold (all \( P < 0.005 \)). The number of motile spermatozoa inseminated was the only factor that significantly influenced both pregnancies and live-birth rates after IUI-D. Indeed, below a threshold of 0.75 million motile spermatozoa inseminated, those rates were significantly lower. Application of this number of motile spermatozoa inseminated threshold may help centers to allocate donations more effectively while maintaining reasonable waiting times for patients.

Asian Journal of Andrology (2022) 24, 287–293; doi: 10.4103/aja202149; published online: 24 September 2021

Keywords: intrauterine insemination; male infertility; number of motile spermatozoa inseminated; sperm donor

INTRODUCTION
Intrauterine insemination with donor sperm (IUI-D) is the most commonly used assisted reproductive technology (ART) for couples seeking a pregnancy in the context of definitive male infertility. The IUI-D procedure is simple, effective, inexpensive, and noninvasive. In the absence of gynecological problems, IUI-D, therefore, has a very good risk–benefit ratio.

The woman’s age is known to be a predictive factor for pregnancy in ART and thus in IUI-D.1-5 The existence of other factors influencing the outcome of IUI-D is subject to debate; although this topic has been studied intensively, the results are conflicting. Putative factors related to the recipient couple include the ovarian reserve,2-4 the etiology of male infertility,5 and the impact of previous pregnancies and deliveries.1,2,4-6 Donor-related factors include sperm parameters before and after thawing,4,7-11 impact of male’s age,7,12-14 and whether pregnancies have already been obtained with donation.5 Finally, the characteristics and conditions of the attempt itself have been studied, e.g., the use of ovarian stimulation or the need for a two-follicle response to obtain higher pregnancy rates.2,5-17

In the current study, we had analyzed procedure-, couple-, and donor-related factors for IUI-D carried out at Lille University Medical Center (Lille, France) over the last ten years. The study’s primary objective was to identify factors that significantly influenced the clinical pregnancy and/or live birth rates. The study’s secondary objective (in the context of a lack of sperm donor and optimization of the cost-effectiveness of IUI-D) was to determine the minimum required number of motile spermatozoa inseminated (NMSI).

PARTICIPANTS AND METHODS
Study population
This study was approved by the Ethics Committee of Lille University Hospital (Lille, France; Reference DEC20150715-0002). All patients had given prior consent for the use of their clinical, hormonal, and ultrasound records. Data were collected retrospectively from medical records at Lille University Medical Center’s sperm and oocyte bank, using JFIV software (version 1.8.3, RD Services, Langlade, France). For each couple, data on the reason for requesting donor sperm and the history of intracouple ART were collected, when appropriate. For each recipient woman, the age, body mass index (BMI), and ovarian reserve (assessed in the early follicular phase using the anti-Müllerian hormone [AMH], follicle-stimulating hormone [FSH], and estradiol [E2] levels) were noted. Serum AMH levels were measured using an
All women received luteal phase support with vaginal progesterone. The gynecologist introduced the catheter into the cervix and gently syringe. After checking the identities of both members of the couple, the sperm preparation was mounted in a flexible, sterile catheter (Elliocath®, Ellios Bio Tek, Paris, France) and transferred to a sterile chamber. Each sample underwent microbiological testing to ensure the absence of infection or contamination. The remainder of the sample was mixed with a cryoprotectant, according to the supplier's recommendations (Sperm Freezing Medium, Medicult, Malov, Denmark; and Sperm Maintenance Medium, Irvine Scientific, Santa Anna, CA, USA), packaged in “high security” 300 μl straws, and identified with the donor code, sample code, current date, and a color. These straws were then thermally welded and frozen by exposure to nitrogen vapor (Freezal, Air Liquide, Paris, France; and Nanodigitcool, CryoBioSystem). At last, the straws were stored at −196°C in liquid nitrogen tanks.

**Sperm cryopreservation**
After liquefaction, each sperm sample was prepared and packaged into “high security” straws (CryoBioSystem, L’Aigle, France). Motility was manually assessed by microscopic examination between the slide and the coverslip. The spermatozoa were counted in a counting chamber. Each sample underwent microbiological testing to ensure the absence of infection or contamination. The remainder of the sample was mixed with a cryoprotectant, according to the supplier's recommendations (Sperm Freezing Medium, Medicult, Malov, Denmark; and Sperm Maintenance Medium, Irvine Scientific, Santa Anna, CA, USA), packaged in “high security” 300 μl straws, and identified with the donor code, sample code, current date, and a color. These straws were then thermally welded and frozen by exposure to nitrogen vapor (Freezal, Air Liquide, Paris, France; and Nanodigitcool, CryoBioSystem). At last, the straws were stored at −196°C in liquid nitrogen tanks.

**Intrauterine insemination**
IUI-D was performed after mono or pauci-follicular ovarian stimulation with gonadotropins. The goal was to develop one or two ovarian follicles. Ovarian stimulation was monitored with endovaginal pelvic ultrasound and serum assays for E2, luteinizing hormone (LH), and progesterone. Once the triggering criteria had been met (between 1 and 3 follicles greater than 15 mm in diameter, concordant estradiolemia [at least 150 pg ml⁻¹ per mature follicle], and absence of a spontaneous LH surge), the decision to trigger ovulation was made at the daily staff meeting by gynecologists and biologists from the ART team. The patient self-injected a 250 μg bolus of recombinant human chorionic gonadotropin (hCG; Ovitrelle®, Merck-Serono, Geneva, Switzerland) at a specific time following the medical prescription. The IUI-D procedure took place 36 h to 38 h after the injection.

On the day of the IUI-D procedure, the couple went to collect the sperm straws from the sperm bank and brought them to the ART laboratory. The sperm were prepared in a sterile manner approximately one hour before the IUI-D procedure. After thawing, the spermatozoa were selected by density gradient (two layers; Puresperm®, Nicadon Malmö, Sweden) and centrifugation. After a washing step, the pellet was concentrated to a volume of 250 μl. Next, the number and motility of the spermatozoa were evaluated to determine the NMSI (% progressive motility × sperm concentration after treatment × 0.25). Next, the sperm preparation was mounted in a flexible, sterile catheter (Elliocath®, Ellios Bio Tek, Paris, France) and transferred to a sterile syringe. After checking the identities of both members of the couple, the gynecologist introduced the catheter into the cervix and gently deposited the sperm preparation at the bottom of the uterine cavity. All women received luteal phase support with vaginal progesterone (200 mg twice daily, morning and evening), which was initiated on the evening of the IUI-D procedure.

**Diagnosis of clinical pregnancy**
We screened for clinical pregnancies 14 days after IUI-D. A clinical pregnancy was defined as a blood hCG level above 100 IU l⁻¹ and was confirmed when a fetal heartbeat was detected on an ultrasound scan 6 to 8 weeks after the IUI-D procedure.

**Inclusion**
All IUI-D procedures carried out at the Lille University Medical Center between January 1, 2007, and December 31, 2017, were included in the study. The patients' follow-up was censured at delivery (if produced) or at the end of the IUI-D program.

**Statistical analyses**
Categorical variables were described by the number (percentage), and continuous variables were described by the median (interquartile range). The normality of the distribution was check graphically and using the Shapiro–Wilk test.

A generalized linear mixed model with a random effect for the patient (to take account of the correlation between a patient's IUI-D attempts) was performed to identify associated factors with the occurrence of clinical pregnancy. Variables associated at the level of 0.20 were introduced in a multivariate model. The same methodology was applied to highlight factors associated with the occurrence of live birth.

The predictive value of the NMSI was assessed using the area under the receiver-operating characteristics (ROC) curve (AUC) and the optimal threshold was determined by maximizing the Youden index. The sensitivity, the specificity, the positive predictive value (PPV), and the negative predictive value (NPV) of the thresholds were expressed with their 95% confidence intervals (CIs). The clinical pregnancy rate and the live birth rate were compared according to the threshold of 0.75 million of NMSI using a Chi-square test. A level of P < 0.05 was adopted for significance. Statistical testing was done at the two-tailed α level of 0.05. Data were analyzed using the SAS software package, release 9.4 (SAS Institute, Cary, NC, USA).

This retrospective study was registered with the French National Data Protection Commission (Commission nationale de l'informatique et des libertés, Paris, France).

**RESULTS**
We included 322 couples, of which 240 (74.5%), 60 (18.6%), and 22 (6.8%) had been referred for azoospermia, severe sperm alterations, and transmissible genetic disease, respectively. The 322 couples underwent a total of 1179 IUI-D procedures, of which 277 resulted in a clinical pregnancy (i.e., giving a pregnancy rate per cycle of 23.5%). Two hundred and twenty-three cycles resulted in a live birth (including 13 sets of twins and one set of triplets), giving a live birth rate of 18.9% per cycle and a multiple pregnancy rate of 6.3% among live birth.

Samples from 179 different sperm donors had been used for the 1179 cycles. Nine couples had not fathered any children before their donation. The donors' clinical characteristics are summarized in Table 1. In 933 attempts, the donor’s straws had already been distributed and had resulted in one or more pregnancies after IUI-D.

The study couple's characteristics are summarized in Table 1. In our series, 93 couples had a history of ART (in vitro fertilization [IVF] with or without intra-cytoplasmic sperm injection [ICSI]). Each woman's
Table 1: Characteristics of intrauterine insemination attempt

| Variable                                      | n  | Overall population |
|-----------------------------------------------|----|--------------------|
| **Women characteristic**                     |    |                    |
| Age (year), mean±s.d.                         | 1179| 33.1±4.2           |
| BMI (kg m⁻²), median (IQR)                   | 1006| 24 (21–28)         |
| AMH (pmol l⁻¹), median (IQR)                 | 1039| 22.9 (13.9–39.1)   |
| FSH on D3 (UI l⁻¹), median (IQR)             | 1131| 5.9 (4.9–7.2)      |
| E2 on D3 (pg ml⁻¹), median (IQR)             | 1119| 36.0 (28.0–45.0)   |
| Previous ART, n (%)                          | 322 | 93 (28.9)          |
| **Donor characteristic**                     |    |                    |
| Age (year), mean±s.d.                        | 179 | 36.1±5.5           |
| BMI (kg m⁻²), median (IQR)                   | 179 | 24.7 (22.6–27.0)   |
| Previous pregnancy with donation, n (%)      | 1172| 933 (79.6)         |
| **Ovarian stimulation and spermatic preparation** |    |                    |
| IUI cycles with follicles ≥15 mm on TD, n    | 1140|                   |
| IUI cycles with <2 follicles (≥15 mm on TD), n (%) | 856 | 75.1               |
| IUI cycles with ≥2 follicles (≥15 mm on TD), n (%) | 284 | 24.9               |
| E2 on TD (pg ml⁻¹), median (IQR)             | 1127| 235 (171–340)      |
| NMSI (million per 250 µl), median (IQR)      | 1132| 1.25 (0.75–2.0)    |

*At IUI attempt level (total=1179); at couple level (total=322); at donor level (total=180). s.d.: standard deviation; BMI: body mass index; IQR: interquartile range; AMH: anti-Müllerian hormone; FSH: follicle-stimulating hormone; D3: day 3 of menstrual cycle; E2: estradiol; TD: triggering day; ART: assisted reproductive technology; NMSI: number of motile spermatozoa inseminated; IUI: intrauterine insemination.

Figure 1: ROC curves and AUC for diagnostic values of the NMSI in (a) pregnancy rate and (b) live birth rate. ROC: receiver-operating characteristics; AUC: area under curve; NMSI: number of motile spermatozoa inseminated.

The cumulative live birth rate for rank 4 was 45.9% for procedures below the NMSI threshold and 70.2% for procedures above or at the NMSI threshold (P = 0.0004); for rank 6, the values were 69.2% and 82.1%, respectively (P = 0.033). The cumulative live birth rate for rank 4 was 36.7% below the NMSI threshold and 63.3% above or at the NMSI threshold (P = 0.002); for rank 6, the values were 56.9% and 73.8%, respectively (P = 0.32).

By regarding both women's age and NMSI threshold, we observed that cumulative pregnancy and live birth rates were higher when more than 0.75 million motile spermatozoa were inseminated despite of women's age (Figure 3).

**DISCUSSION**

The primary objective of the present study was to identify factors that influenced the outcome of IUI-D. The study's secondary objective was to optimize the distribution of donor sperm donation by setting an NMSI threshold.

The pregnancy rates per IUI-D cycle reported in the literature range from 6.1% to 28.1%, and the birth rates range from 5% to 22%.

In our study, the pregnancy rate per cycle was 23.5%, and the birth rate per cycle was 18.9%. Our rates are similar to the average values for France published in the French Federation of Sperm and Oocyte Banks' annual report for 2015 (24% for pregnancies and 18.6% for live births).

As mentioned above, our study included all IUI-D procedures performed at Lille University Medical Center between January 1, 2007, and December 31, 2017. All patients were stimulated with gonadotropins. Some researchers have demonstrated the superiority of ovarian stimulation with gonadotropins with regard to the IUI-D outcomes, whereas others have not. Stimulation should be moderate and well controlled, so as to avoid the risk of multiple pregnancies. In the present study, we considered that ovarian follicles with a diameter greater than 15 mm were mature. When two or more mature follicles were present, the pregnancy rate (27.5%) was not significantly higher than that for single follicles (22.4%; P = 0.1). This moderate, nonsignificant elevation in pregnancy rates during a twofollicle stimulation contrasts with the literature data.

(95% CI: 77.5% to 87.1%) for the NPV. Similar diagnostic values were found for the live births (data not shown).

In our center, a couple could make up to six IUI-D attempts. We obtained a cumulative pregnancy rate of 64.7% for rank 4 and 79.4% for rank 6. The cumulative live birth rates were 56.3% for rank 4 and 69.4% for rank 6. At last, the cumulative clinical pregnancy and live birth rates according to NMSI <0.75 million versus NMSI ≥0.75 million are represented on the Figure 2. The cumulative pregnancy rate for rank 4 was 45.9% for procedures below the NMSI threshold and 70.2% for procedures above or at the NMSI threshold (P = 0.0004); for rank 6, the values were 69.2% and 82.1%, respectively (P = 0.033).
Only the NMSI had an impact on IUI-D outcomes
M Cardey-Lefort et al

In the present study, we recorded 13 twin pregnancies and 1 triplet pregnancy. Eight of the twin pregnancies occurred during a single-follicle cycle. The multiple pregnancy rate was 4.2% overall and 7.7% for multifollicular procedures. The relative increase in the twin pregnancy rate was not statistically significant and thus contrasts with literature reports. The only triple pregnancy came from a cycle with three mature follicles. In our center, we rarely apply two-follicle stimulation for IUI-D procedures. Although the objective is to obtain a pregnancy, physicians and patients must be aware of the elevated risk of multiple pregnancy.

The women’s age is a critical factor in ART. In the present study, the women’s age was found to be negatively associated with live birth in both univariate and multivariate analyses; there was a 40.0% decrease in the likelihood of a live birth per 10-year age increment. It should be noted that our study included a small number of cycles ($n = 44$).

![Figure 2](image1.png) Cumulative (a) pregnancy and (b) live birth rates in function of NMSI. The two curves of cumulative (a) pregnancy and (b) live birth rates are shown in order to compare IUI-D carried out above and under our NMSI’s threshold.

![Figure 3](image2.png) Cumulative (a) pregnancy and (b) live birth rates depending on women’s age and NMSI. Four curves represents cumulative (a) pregnancy and (b) live birth rates in function of women’s ages: younger than 35 years old or older; and also in function of NMSI: lower than 0.75 million or with at least 0.75 million motile spermatozoa inseminated. NMSI: number of motile spermatozoa inseminated; M: million.

Table 2: Associated factors with clinical pregnancy in univariate and multivariate analyses

| Variable                              | n       | Univariate analysis | Multivariate analysis |
|---------------------------------------|---------|---------------------|-----------------------|
|                                       |         | OR (95% CI)         | P                     | OR (95% CI)         | P                     |
| Women characteristic                  |         |                     |                       |                      |                       |
| Age (year)                            | 1179    | 0.73 (0.52–1.02)    | 0.063                 | 0.73 (0.51–1.05)    | 0.091                 |
| BMI (kg m$^{-2}$)                     | 1006    | 1.08 (0.93–1.25)    | 0.33                  |                       |                       |
| AMH                                   | 1039    | Ref                 |                       |                       |                       |
| AMH $<$ 8 pmol l$^{-1}$                |         | 1.22 (0.62–2.40)    | 0.57                  |                       |                       |
| FSH on D3                             | 1131    | Ref                 |                       |                       |                       |
| FSH on D3 $<$ 10 UI l$^{-1}$          |         | 1.00 (0.55–1.79)    | 0.99                  |                       |                       |
| FSH on D3 $>$ 10 UI l$^{-1}$          |         | Ref                 |                       |                       |                       |
| E2 on D3 (pg ml$^{-1}$)               | 1119    | 0.91 (0.83–1.00)    | 0.052                 | 0.91 (0.83–1.00)    | 0.052                 |
| Previous ART, yes versus no           | 1179    | 0.71 (0.51–0.99)    | 0.044                 | 0.71 (0.51–0.99)    | 0.096                 |
| Previous pregnancy, yes versus no     | 1179    | 1.05 (0.79–1.40)    | 0.73                  |                       |                       |
| Previous live birth, yes versus no    | 1179    | 1.08 (0.79–1.49)    | 0.62                  |                       |                       |
| Donor characteristic                  |         |                     |                       |                      |                       |
| Age (year)                            | 1174    | 1.15 (0.90–1.47)    | 0.27                  |                       |                       |
| BMI (kg m$^{-2}$)                     | 1174    | 1.02 (0.83–1.26)    | 0.85                  |                       |                       |
| Previous pregnancy with donation$^{a}$| 1172    | 0.99 (0.64–1.26)    | 0.53                  |                       |                       |
| Ovarian stimulation and spermatic preparation | | | | | |
| IUI cycles with follicles $\geq$ 15 mm on TD | 1140   | Ref                 |                       | Ref                 |                       |
| IUI cycles with $<$ 2 follicles (15 mm on TD) | | | | | |
| IUI cycles with $\geq$ 2 follicles (15 mm on TD) | 1127   | 1.32 (0.97–1.80)    | 0.082                 | 1.36 (0.98–1.89)    | 0.067                 |
| E2 on TD (pg ml$^{-1}$)               | 1132    | 1.04 (0.97–1.13)    | 0.27                  |                       |                       |
| NMSI (million per 250 $\mu$l)         |         | 1.14 (1.04–1.25)    | 0.005                 | 1.18 (1.07–1.29)    | $<0.001$              |

$^{a}$OR calculated for 1-unit increase; $^{b}$OR calculated for 5-unit increase; $^{c}$calculated for 10-unit increase; $^{d}$calculated for 100-unit increase. Ref: reference; OR: odds ratio; CI: confidence interval; BMI: body mass index; AMH: anti-Müllerian hormone; FSH: follicle-stimulating hormone; D3: day 3 of menstrual cycle; E2: estradiol; TD: triggering day; ART: assisted reproductive technology; $-$: multivariate analysis not performed; IUI: intrauterine insemination; NMSI: number of motile spermatozoa inseminated.
in women over the age of 40. In this small group, the pregnancy and birth rates were 18.2% and 13.6%, respectively, i.e., 8 pregnancies and 6 births, two of which were twin births. Other researchers have reported on the decline in female fertility from the age of 38 onward.\(^{4,7,22}\) The mean age was higher in women with a history of autologous ART (34.3 years) than that in those without (32.5 years). However, this difference was not statistically significant (\(P = 0.37\)). The lower pregnancy and birth rates for these couples cannot therefore solely be explained by the women’s older age. The indication of IUI-D after the failure of IVF-ICSI is widely accepted in practice and in the literature.\(^{5,7,21,22}\) Our present results and a number of other studies have shown that pregnancy and birth rates for IUI-D are lower after the failure of IVF-ICSI.\(^{4,22}\) Hence, one can reasonably hypothesize that another factor for female infertility remains to be discovered in the partners of men with oligozoospermia – preventing them from compensating for sperm anomalies.\(^{26}\) Nevertheless, IUI-D remains an option when IVF/ICSI with the male spouse’s sperm has failed and the woman’s fertility is not objectively impaired.

In the present study, the woman’s characteristics (such as ovarian status [AMH, FSH, and E2 levels] and a history of pregnancies and deliveries) were not significantly related to the chances of pregnancy and birth after IUI-D. This could be explained by the fact that the women admitted to donor sperm programs also have etiologic infertility (endometriosis, tubal infertility and/or pelvic adhesion) and are directly steered toward IVF-ICSI with sperm donor. A recent study found that the AMH level does not predict the success of IUI-D.\(^{23}\) Like our present results, these findings emphasize that AMH is irrelevant outside the context of controlled ovarian hyperstimulation. In our study, previous pregnancy or childbirth was not predictive of successful IUI-D. The literature data on this topic are contradictory.\(^{1,4,6}\)

In line with most of the literature data, we found that the woman’s BMI did not influence pregnancy or birth rates in IUI-D.\(^{2,4}\) We also observed that donor age was not associated with the pregnancy and birth rates. This was probably due to the donor age limit imposed by the French legislation. A retrospective study of 2142 IUI-D cycles in women under 40 found that donor age of 45 was associated with lower pregnancy rates.\(^{44}\) Other researchers have reported that along with a lower likelihood of pregnancy, advanced donor age is associated with an elevated risk of psychiatric diseases, polycystic ovaries, and Down syndrome (trisomy 21) in the children.\(^{5,13,14,26}\) We consider that these risks justify the age limit imposed on sperm donors in France. Moreover, in our study, the sperm donors’ screening reveals the importance of sperm quality in achieving pregnancy in women over 35 years of age (Figure 3).

With regard to sperm parameters, our results differ markedly from the literature data.\(^{7,11,27,28}\) In the present study, the most important factor influencing pregnancy and birth rates was the NMSI. This topic is subject to debate. Some researchers have found that pregnancy did not depend on the NMSI in these studies.\(^{16}\) The mean NMSI was 1.7 million, and 403 IUI-D procedures (34.2%) were performed with an NMSI below 1 million. Hence, the present study is one of the first to have evaluated results obtained with such a low NMSI.

In France, sperm donation is unpaid and voluntary; hence, donations must be optimized to meet the demand from infertile

Table 3: Results of univariate and multivariate statistical analyses about IUI-D characteristics’ effect on live-birth outcomes

| Variable | n   | Univariate analysis OR (95% CI) | \(P\) | Multivariate analysis OR (95% CI) | \(P\) |
|----------|-----|---------------------------------|------|---------------------------------|------|
| Women characteristic |     |                                 |      |                                  |      |
| Age (year) | 1179 | 0.63 (0.43–0.94)\(^{a}\) | 0.022 | 0.64 (0.41–0.99) | 0.045 |
| BMI (kg m\(^{-2}\)) | 1006 | 1.07 (0.90–1.29)\(^{a}\) | 0.44  | –                                | –    |
| AMH | 1039 | Ref | – | – | – |
| AMH <8 pmol \(\text{L}^{-1}\) | Ref | – | – | – | – |
| AMH ≥8 pmol \(\text{L}^{-1}\) | 1172 | 1.19 (0.54–2.59) | 0.67  | – | – |
| FSH on D3 | 1131 | 1.19 (0.58–2.45) | 0.64  | – | – |
| FSH on D3 <10 UI \(\text{L}^{-1}\) | Ref | – | – | – | – |
| FSH on D3 ≥10 UI \(\text{L}^{-1}\) | Ref | – | – | – | – |
| E2 on D3 (pg ml\(^{-1}\)) | 1119 | 0.91 (0.81–1.02)\(^{a}\) | 0.097 | 0.90 (0.80–1.01) | 0.072 |
| Previous ART, yes versus no | 1179 | 0.61 (0.41–0.90) | 0.014 | 0.61 (0.41–0.90) | 0.061 |
| Previous pregnancy, yes versus no | 1179 | 0.97 (0.70–1.35) | 0.85  | – | – |
| Previous live birth, yes versus no | 1179 | 1.17 (0.82–1.67) | 0.39  | – | – |
| Donor characteristic |     |                                 |      |                                  |      |
| Age (year) | 1174 | 1.22 (0.93–1.61)\(^{a}\) | 0.16  | 1.23 (0.91–1.66) | 0.18  |
| BMI (kg m\(^{-2}\)) | 1174 | 0.98 (0.78–1.24)\(^{a}\) | 0.88  | – | – |
| Previous pregnancy with donation\(^{a}\) | 1172 | 0.83 (0.57–1.20) | 0.32  | – | – |
| Ovarian stimulation and spermatic preparation |     |                                 |      |                                  |      |
| IUI cycles with follicles ≥15 mm on TD | 1140 | Ref | – | – | – |
| IUI cycles with <2 follicles (≥15 mm on TD) | Ref | – | – | – | – |
| IUI cycles with ≥2 follicles (≥15 mm on TD) | 1127 | 1.30 (0.92–1.83) | 0.14  | 1.26 (0.85–1.87) | 0.25  |
| E2 on TD (pg ml\(^{-1}\)) | 1127 | 1.08 (0.99–1.17)\(^{a}\) | 0.090 | 1.08 (0.98–1.19) | 0.13  |
| NMSI (million per 250 µl) | 1132 | 1.15 (1.04–1.26)\(^{a}\) | 0.007 | 1.19 (1.07–1.32) | 0.001 |

\(^{a}\)OR calculated for 1-unit increase; \(^{b}\)OR calculated for 5-unit increase; \(^{c}\)OR calculated for 10-unit increase; \(^{d}\)calculated for 100-unit increase. Ref: reference; OR: odds ratio; CI: confidence interval; BMI: body mass index; AMH: anti-Müllerian hormones; FSH: follicle-stimulating hormone; D3: day 3 of menstrual cycle; E2: estradiol; TD: triggering day; ART: assisted reproductive technology; \(\sim\) multivariate analysis not performed; IUI: intrauterine insemination; IUI-D: intrauterine insemination with donor sperm; NMSI: number of motile spermatozoa inseminated.
patients. An optimal threshold of NMSI of 1 million was found in our study as in previous studies22–29 and as recommended by the French National Guidelines on ART for IUI with couple sperm (IUI-C). However, the predictive value of the NMSI is low (AUC = 0.56, 95% CI: 0.52 to 0.59), so no threshold seems to be obvious. A threshold of 0.75 million of NMSI had a PPV and an NPV not significantly different from the threshold of 1 million (PPV of 0.75 million vs 1 million: 25.9% [95% CI: 23.0% to 28.9%] vs 26.5% [95% CI: 23.3% to 29.8%]; NPV of 0.75 million vs 1 million: 82.7% [95% CI: 77.5% to 87.1%] vs 80.6% [95% CI: 76.4% to 84.4%]). A study conducted in seven ART centers in France30 showed that beyond 1 million, the NMSI had no influence on the pregnancy and birth rates following IUI-C.

Our results indicate that IUI-D and IUI-C differ with regard to the NMSI and the number of attempts before referral for IVF. In fact, women of infertile men in donor sperm programs have not usually ever been pregnant - with the exception of women with a history of intracouple ART attempts, which might explain the negative association for our IUI-D results. However, the gynecologists at our center tend to change their technical strategy rapidly and (in line with the French National Guidelines on ART) offer IUI after of 3 or 4 intracouple IUI procedures have failed. The gynecologists often apply the same pattern to IUI-D, although our results emphasize the clear benefit of carrying out a fifth and even a sixth attempt before turning to IVF-ICSI. This result is not in line with the literature data.22,23 Given the difficulty, risks and cost of IVF-ICSI treatment and the absence of significantly higher associated pregnancy and birth rates, it makes sense to carry out all six IUI-D attempts.

Our study could comfort ART centers in optimizing each valuable sperm donation by lowering the esteemed number of mobile spermatozoa per straw. And, in countries where ART’s cost is supported by patients, our results could help to reduce the cost of procedure using sperm donor by decreasing the number of straws needed to reach fair chances of success.

CONCLUSION
The NMSI was the only associated factor with both pregnancy and live birth after multivariate analysis. The woman’s age was the second factor highlighted for live birth only. A threshold of 0.75 million of NMSI was found as efficient to provide good chances of pregnancy and live birth to patients. The use of this lower NMSI threshold than the one usually employed does not reduce the analytical performances of it to predict IUI-D success. That is why its application is relevant in the current context (a shortage of donations, and ever-increasing waiting times for patients).

AUTHOR CONTRIBUTIONS
MCL collected data and drafted the manuscript. BD conceived the study and participated in its coordination. AU helped to collect data. HB performed the statistical analysis and helped to draft the manuscript. ALB participated in the study design and helped to draft the manuscript. GR conceived the study, and participated in its design and helped to draft the manuscript. All authors read and approved the final manuscript.

COMPETING INTERESTS
All authors declare no competing interests.

REFERENCES
1 Botchan A, Hauser R, Gamzu R, Yogeè L, Paz G, et al. Results of 6139 artificial insemination cycles with donor spermatozoa. Hum Reprod 2001; 16: 2298–304.
2 Thijsen A, Cremers A, Van der Elst W, Cremers E, Vandormael E, et al. Predictive factors influencing pregnancy rates after intrauterine insemination with frozen donor semen: a prospective cohort study. Reprod Biomed Online 2017; 34: 590–7.
3 Boulard V, Charbit B, Brasseur F, Lourdel E, Copin H, et al. Prognostic factors of pregnancy in intra-uterine insemination with sperm of donor: a review of 535 cycles over 7 years. J Gynaecol Obstet Biol Reprod (Paris) 2013; 42: 40–8.
4 Molkad C, Clavier B, Perdrix A, Roman H, Marpeau L, et al. Prognosis factors in donor semen insemination: a 10-years follow-up study of 188 patients. Gynecol Obstet Fertil 2013; 41: 96–104.
5 Bahadur G, Farhi J, Ling KL, Tchetchiraisik K, Ashraf H, et al. Pregnancy and miscarriage rates in 3978 donor insemination cycles: effect of age, parity and partner’s infertility status on pregnancy outcome. Hum Fertil (Camb) 2000; 3: 207–13.
6 Shenfield F, Doyle P, Valentine A, Steele SJ, Tan SL. Effects of age, gravidity and male infertility status on cumulative conception rates following artificial insemination with cryopreserved donor semen: analysis of 2998 cycles of treatment in one centre over 10 years. Hum Reprod 1993; 8: 60–4.
7 Achard V, Perrin J, Saias-Magnan J, Noizet A, Grillo JM, et al. Optimization of artificial inseminations with donor semen: a four-year experience. Gynecol Obstet Fertil 2005; 33: 877–83.
8 Chavkin DE, Molinaro TA, Roe AH, Sammel MD, Dokras A. Donor sperm insemination cycles: are two inseminations better than one? J Androl 2012; 33: 375–80.
9 Clarke GN, Bourne H, Hill P, Johnston WJ, Spears A, et al. Artificial fertilization and in-vitro fertilization using donor spermatozoa: a report on 15 years of experience. Hum Reprod 1997; 12: 722–6.
10 Eccard R, Cottingin D, Mathieu C, Rabilloud M, Zyba JC. The mean of sperm parameters in semen donations from the same donor. An important prognostic factor in: Int J Androl 1999; 22: 163–72.
11 Fereur T, Jean M, Mairalie S, Langlois ML, Dubourdieu S, et al. Predictive value of National Guidelines on ART for IUI with couple sperm. Int J Androl 2009; 32: 498–504.
12 Khalil MR, Rasmussen PE, Erk B, Laursen SB, Rex S, et al. Intrauterine insemination with donor semen. An evaluation of prognostic factors based on a review of 1131 cycles. Acta Obstet Gynecol Scand 2001; 80: 342–8.
13 Boitelle F, Plouvier P, Dumont A, Barbotin AL, Rigot JM, et al. Effects of father’s age on fertility, results of ART and health of children. Gynecol Obstet Fertil Senol 2017; 45: 28–31.
14 Koh SA, Sanders K, Deakin R, Burton P. Male age negatively influences clinical pregnancy rate in women younger than 40 years undergoing donor insemination cycles. Reprod Biomed Online 2013; 27: 125–30.
15 Ferrara I, Balest R, Grudzinskas JG. Intrauterine insemination with fresh donor sperm. Pregnancy outcome in relation to age and ovarian stimulation regime. Hum Reprod 2002; 17: 2320–4.
16 Kang BM, Wu TC. Effect of age on intrauterine insemination with frozen donor sperm. Obstet Gynecol 1996; 88: 93–8.
17 Le Lannou D, Gastard E, Guivarch A, Laurent MC, Poulain P. Strategies in frozen donor semen procreation. Hum Reprod 1995; 10: 1765–74.
18 De Brucker M, Cambus H, Haentjens P, Francotte J, Verheyen G, et al. Insemination of the oocytes during in vitro fertilization using donor spermatozoa: a report on 15 years of experience. Hum Reprod 2002; 17: 2107–11.
19 Zuzuarregui JL, Meseguer M, Garrido N, Simón C, Pellicer A, et al. Parameters affecting the results in a program of artificial insemination with donor sperm. A 12-year retrospective review of more than 1800 cycles. J Assist Reprod Genet 2004; 21: 109–18.
20 Gorrili MJ, Burny KA, Patton PE. Pregnancy outcomes using donor sperm insemination after failed in vitro fertilization with intracytoplasmic sperm injection cycles in couples with complex infertility disorders. Fertil Steril 2003; 80: 936–8.
21 Leguy MC, Juillard JC, Kunstmann JM, de Ziegler D, Faouque P, et al. ART with sperm donor after intraconjugal ICSI failure. Gynecol Obstet Fertil 2011; 39: 289–95.
22 Hennebicq S, Blagosklonov O, Eustache F, Papaaxthos A, Drueineaud V, et al. Donor sperm insemination after failed intra-couple intracytoplasmic sperm injection. Syst Biol Reprod Med 2017; 11: 1–8.
23 Emperaire JC, Gauzere E, Audebert A. Female fertility and donor insemination. Lancet 1980; 1: 1423–4.
24 González-Forreria I, Martínez F, Rodríguez-Purata J, Ballester M, Al-Congenital malformations.
25 Alonso-Mosquera V, González-Foruria I, Martínez F, Rodríguez-Purata J, Ballester M, et al. Donor sperm inseminations? Lancet 2004; 21: 109–18.
26 Shenfield F, Doyle P, Valentine A, Steele SJ, Tan SL. Effects of age, gravidity and male infertility status on cumulative conception rates following artificial insemination with cryopreserved donor semen: analysis of 2998 cycles of treatment in one centre over 10 years. Hum Reprod 1993; 8: 60–4.
27 Achard V, Perrin J, Saias-Magnan J, Noizet A, Grillo JM, et al. Optimization of artificial inseminations with donor semen: a four-year experience. Gynecol Obstet Fertil 2005; 33: 877–83.
28 Chavkin DE, Molinaro TA, Roe AH, Sammel MD, Dokras A. Donor sperm insemination cycles: are two inseminations better than one? J Androl 2012; 33: 375–80.
29 Clarke GN, Bourne H, Hill P, Johnston WJ, Spears A, et al. Artificial fertilization and in-vitro fertilization using donor spermatozoa: a report on 15 years of experience. Hum Reprod 1997; 12: 722–6.
30 Eccard R, Cottingin D, Mathieu C, Rabilloud M, Zyba JC. The mean of sperm parameters in semen donations from the same donor. An important prognostic factor in: Int J Androl 1999; 22: 163–72. 
31 Fereur T, Jean M, Mairalie S, Langlois ML, Dubourdieu S, et al. Predictive value of
of 2821 cycles in 1355 couples. Andrologia 2016; 48: 29–36.

28 Johnston RC, Kovacs GT, Lording DH, Baker HW. Correlation of semen variables and pregnancy rates for donor insemination: a 15-year retrospective. Fertil Steril 1994; 61: 355–9.

29 Monraisin O, Chansel-Debordeaux L, Chiron A, Floret S, Cens S, et al. Evaluation of intrauterine insemination practices: a 1-year prospective study in seven French assisted reproduction technology centers. Fertil Steril 2016; 105: 1589–93.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

©The Author(s)(2021)